Furthermore, as reported in a phase II/III clinical trial30, pembrolizumab showed more significant benefits to non-squamous NSCLC patients compared with squamous NSCLC patients, implicating that non-squamous NSCLC might be a more suitable indication for PD-1 inhibitors with higher efficiency and lower toxicity. Here, PDCD1 is linked to non-small cell lung carcinoma.